EDIT
Editas Medicine, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for low
